Several UK medical products have obtained accelerated market access through Hainan’s Lecheng Policy Framework
in ChinaTrade barrier summary
Hainan’s Lecheng Policy Framework features pilot policies that allow fast-track pathways for the early import, clinical use and commercialisation of overseas medical products ahead of National Medical Products Administration (NMPA) approval.
Despite these opportunities, foreign companies faced a complicated process involving multiple regulators. They also needed to navigate how these policies worked in practice.
As a result, UK government has facilitated technical exchanges with key Chinese regulators, giving UK businesses clearer insight into complex local policies and market-entry routes. The team also helped UK businesses establish connections with Chinese partners to support localisation and faster market entry.
Through this work, several small and medium enterprises (SMEs) accessed fast-track pathways via local partnerships, resulting in shorter market access timelines. While this has delivered successful outcomes for those involved, UK government continues to work with Hainan regulatory bodies to track policy developments and co-develop a fast-track framework that better supports more UK businesses and meets their needs.
Sectors affected
- Medical devices and equipment
- Pharmaceuticals and biotechnology
Resolved
Yes - June 2025
Date reported
17 December 2025
Last updated
11 March 2026
Public ID
PID-G3MAPB
If a trade barrier is affecting your exports or investment from the UK, please let us know on report a trade barrier .
If you export goods you can check duties and customs procedures for your chosen market.